Antivirals for non-HIV Flashcards
Biosynthesis of a toxin from a non-toxic precursor
Common in nucleoside analogues that must phosphorylated to incorporate into viral DNA
Lethal synthesis
MOA of acyclovir and valacyclovir
Inhibit viral DNA synthesis through lethal synthesis
Drugs are monophosphates; host enzymes convert them to inhibitive triphosphates that terminate viral DNA synthesis
Acyclovir and valacyclovir lethal synthesis requires these 2 types of enzymes
Viral nucleoside kinase expression to phosphorylate drug (monophosphate)
Host enzymes to convert monophosphate to triphosphate form
Valacyclovir is converted to this in a first pass hydrolysis reaction
Acyclovir
This is converted to acyclovir in a first pass hydrolysis reaction
Valacyclovir
2 indications for acyclovir and valacyclovir
Herpes infections
Cytomegalovirus infections
3 main adverse effects of acyclovir and valacyclovir
Reversible renal dysfunction (crystallization of drug in renal tubule and collecting duct)
Neurological and renal toxicity with high dose or IV infusion
Thrombocytopenia purpura-hemolytic uremic syndrome (potentially fatal; most frequent in immunocompromised patients)
Reversible renal dysfunction, neurological and renal toxicity with high dose or IV infusion, and thrombocytopenia purpura-hemolytic uremic syndrome are adverse effects of these drugs
Acyclovir and valacyclovir
Thrombocytopenic purpura-hemolytic uremic syndrome is a potentially fatal adverse effect of these drugs
Is most frequent in immunocompromised patients
Acyclovir and valacyclovir
MOA of cidofovir
Lethal synthesis to activated cidofovir diphosphate (requires only host enzymes)
Cidofovir diphosphate incorporated into DNA slows or stops DNA pol activity
Drug that given concurrently reduces cidofovir toxicity
Probenecid
Blocks anion transporter on renal tubular epithelial cells that mediates cidofovir uptake
Probenecid given concurrently reduces the toxicity of this drug
Cidofovir
Black box warning of Cidofovir
Nephrotoxicity
MOA of Foscarnet
Competitive inhibitor of viral DNA polymerase
NO lethal synthesis required
2 adverse effects (black box warnings) of Foscarnet
Renal toxicity
CNS disturbances (including seizures)
Drug with renal toxicity as an adverse effect; should avoid concurrent use with other nephrotoxic drugs
Electrolyte disturbances in acute overdosage
Foscarnet
With foscarnet, concurrent use with these should be avoided
Other nephrotoxic drugs
These can occur in acute overdosage of foscarnet
Electrolyte disturbances
3 adverse effects of Ganciclovir and Valganciclovir
Acyclovir-like adverse reactions (renal dysfunction, neurological toxicity, thrombocytopenic purpura-hemolytic uremic syndrome)
Bone marrow suppression
Teratogenic, mutagenic, and oncogenic potential
4 black box warnings of Ganciclovir and Valganciclovir
Hematological toxicities
Carcinogenic and teratogenic activity
Aspermatogenesis
Appropriate oral and IV use only (ganciclovir only)